Company Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Pharmaceuticals

Real-time Estimate Cboe Europe 05:08:14 2024-03-28 am EDT 5-day change 1st Jan Change
69.75 CHF -0.21% Intraday chart for Cosmo Pharmaceuticals N.V. +9.45% +36.54%

Business Summary

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.

Number of employees: 319

Sales per Business

CHF in Million2021Weight2022Weight Delta
Own Products
52.0 %
43 60.6 % 53 52.0 % +25.05%
Licence Fees, Up-front Fees and Milestones
23.8 %
6 8.5 % 24 23.8 % +310.51%
Generic Products, Specialty Drugs and Related Services
12.9 %
14 19.4 % 13 12.9 % -3.41%
Royalties
9.7 %
6 8.6 % 10 9.7 % +63.17%
Other
1.6 %
2 2.9 % 2 1.6 % -17.40%

Sales per region

CHF in Million2021Weight2022Weight Delta
Italy
100.0 %
70 100.0 % 102 100.0 % +45.72%

Managers

Managers TitleAgeSince
Chief Executive Officer 61 05-12-31
Director of Finance/CFO 52 16-05-31
Chief Tech/Sci/R&D Officer 54 -
Chief Tech/Sci/R&D Officer 45 05-05-31
Chief Tech/Sci/R&D Officer 51 11-08-31
Chief Operating Officer 60 00-12-31
Investor Relations Contact 53 22-01-09
Corporate Officer/Principal 45 -
Human Resources Officer 50 -
Corporate Officer/Principal 57 21-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 57 21-05-27
Founder 69 96-12-31
Director/Board Member 64 05-12-31
Director/Board Member 69 12-03-31
Director/Board Member 65 16-02-29
Chief Executive Officer 61 05-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 17,543,522 7,842,715 ( 44.70 %) 1,490,681 ( 8.497 %) 44.70 %

Shareholders

NameEquities%Valuation
6,099,563 34.77 % 456 M CHF
1,467,623 8.366 % 110 M CHF
1,283,390 7.315 % 96 M CHF
dievini Hopp BioTech holding GmbH & Co. KG
3.797 %
666,062 3.797 % 50 M CHF
UBS Asset Management Switzerland AG
2.990 %
524,551 2.990 % 39 M CHF
Helaba Invest Kapitalanlagegesellschaft mbH
0.7384 %
129,549 0.7384 % 10 M CHF
Sp-Fund Management Co. Ltd.
0.5706 %
100,102 0.5706 % 7 M CHF
3V Asset Management AG
0.2374 %
41,656 0.2374 % 3 M CHF
FIL Investments International (Italy)
0.1674 %
29,376 0.1674 % 2 M CHF
Oddo BHF Asset Management GmbH
0.1083 %
19,000 0.1083 % 1 M CHF

Holdings

NameEquities%Valuation
1,283,390 7.32% 96,048,381 $
69,000,010 0.58% 4,250,401 $

Company contact information

Cosmo Pharmaceuticals NV

Riverside II Sir John Rogerson's Quay

2, Dublin

+353 1 817 0370

http://www.cosmopharma.com
address Cosmo Pharmaceuticals N.V.(COPN)

Group companies

NameCategory and Sector
Pharmaceuticals: Major
Pharmaceuticals: Major
Granell Strategic Investment Fund Ltd.
Investment Managers

Sales per Business

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
71.35 EUR
Average target price
95.67 EUR
Spread / Average Target
+34.08%
Consensus